Latest News
BriaCell Therapeutics Corp.
- BriaCell Bets an Off-the-Shelf Cell Vaccine Can Extend Life After ADCs in Metastatic Breast Cancer
- BriaCell Therapeutics Corp. Estimates – BOATS:BCTXZ
- BriaCell Therapeutics Corp (TSX:BCT): Why Execution Matters More Than Headlines for Canadian Market Watchers
- BriaCell Announces ESMO 2026 Poster Highlighting Circulating Immune Biomarker Associated with Clinical Outcomes in Metastatic Breast Cancer
- BriaCell Therapeutics Corp. (TSX:BCT) Gains Bullish Momentum as Cancer Immunotherapy Progress Strengthens Investor Optimism
- BriaCell Therapeutics Warrant (BCTXZ) Edges Down 2.36% to $0.16 as Price Pins Near $0.15 Support - Outside Reversal
- BriaCell CEO William Williams: An Off-the-Shelf Cell Therapy Doubled Survival in Late-Stage Breast Cancer—the Phase 3 Readout Decides What Comes Next
- BriaCell Therapeutics Warrant (BCTXL) Trades Near $0.90 as Range Holds - Swing Trade Setups
- BriaCell Therapeutics Warrant (BCTXZ) Drops 15.6% to $0.21 as $0.20 Support Comes Into Focus - Dynamic Hedging
- BriaCell and BriaPro to Present Four Posters at SITC 2026 Annual Meeting
- BriaCell Therapeutics Corp. (TSX:BCT) Extends Green Momentum as Investor Confidence Improves
- BriaCell’s Bria-ABC Joins Roster of US-Enrolled Breast Cancer Trials
Headlines from the last 30 days, linking to the original publishers. See all market news →